Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00232583 · ClinicalTrials.gov registry record · NA
Preservation of Beta-cell Function in Type 2 Diabetes Mellitus
A NA study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 58
- Enrollment target
NCT00232583 is a NA study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 58 participants.
The verdict
NCT00232583, a NA study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 58 participants
- Enrollment target
Study Summary
The study evaluates the rate beta-cell function decline in newly diagnosed type 2 diabetic patients on two different treatment regimens: insulin and metformin versus glyburide, metformin and pioglitazone.
Interventions
- DRUG Metformin
- DRUG Pioglitazone
- DRUG Insulin
- DRUG glyburide
- DRUG Metfomin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2003-11 |
| Est. Completion | 2011-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00232583
The ClinicalTrials.gov registry entry for NCT00232583 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Metformin is the first listed.
NCT00232583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00232583 about?
NCT00232583 is a clinical study titled "Preservation of Beta-cell Function in Type 2 Diabetes Mellitus". The study evaluates the rate beta-cell function decline in newly diagnosed type 2 diabetic patients on two different treatment regimens: insulin and metformin versus glyburide, metformin and pioglitazone.
What is the current status of trial NCT00232583?
This trial is currently completed. It is a NA study. The enrollment target is 58 participants. The study started on 2003-11. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00232583?
The interventions under investigation include: Metformin (DRUG), Pioglitazone (DRUG), Insulin (DRUG), glyburide (DRUG), Metfomin (DRUG).
Who is sponsoring clinical trial NCT00232583?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.